ORIENT BIO Inc.

KSE 002630.KS

ORIENT BIO Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2024: 13.99%

ORIENT BIO Inc. Return on Capital Employed (ROCE) is 13.99% for the year ending March 31, 2024, a 217.40% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

ORIENT BIO Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2023 was -11.92%, a -311.53% change year over year.
ORIENT BIO Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2022 was -2.90%, a 91.11% change year over year.
ORIENT BIO Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2021 was -32.56%, a -50.88% change year over year.
ORIENT BIO Inc. Return on Capital Employed (ROCE) for the year ending March 31, 2020 was -21.58%, a -53.24% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KSE: 002630.KS

ORIENT BIO Inc.

CEO	Mr. Jae-Jin Chang
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	322, Galmachi-ro
Employees	125
Sector	Health Care
Industries Biotechnology

Description

ORIENT BIO Inc. operates in the bio-industry in South Korea. The company produces laboratory animals. In addition, it offers various equipment for research environment. The company was formerly known as Orient Co., Ltd. and changed its name to ORIENT BIO Inc. in 2005. ORIENT BIO Inc. was founded in 1959 and is based in Seongnam, South Korea.

Key trends

Past 5 years